Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Download White Paper
Filter by Type:
Filter by Topic:
Check out our latest white paper! We partnered with Informa Pharma Intelligence to bring you the latest information on COVID19 and its ...
10 min Read.
Pharm-Olam was contracted to execute a non-interventional study with children aged 3 years and younger, who have an Ultra-Rare Disease.
2 min Read.
Pharm-Olam was contracted to assess subcutaneous immunotherapy in adult and pediatric subjects with peanut allergy. The safety of the substance ...
2 min. Read
Pharm-Olam was contracted to manage and recruit four sites for Phase I, first-in-human research of a PD-1 drug treatment for solid tumor ...
A video overview of Pharm-Olam's Rare Disease CRO services.
2 min. Watch
A Pharm-Olam case study of a Phase I/II pediatric Respiratory Distress Syndrome neonate study with a gestational age between 27 and 33 weeks.
We'll only send you one email a month featuring our best content from the month before.